Loading...
XLON
ABDX
Market cap37mUSD
Aug 28, Last price  
11.00GBP
Name

Abingdon Health PLC

Chart & performance

D1W1MN
XLON:ABDX chart
P/E
P/S
3.30
EPS
Div yield, %
Shrs. gr., 5y
30.74%
Rev. gr., 5y
9.99%
Revenues
Net income
CFO

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Abingdon Health Plc is a global enterprise dedicated to the innovation, production, and worldwide distribution of diagnostic technologies. Their diverse product portfolio includes rapid self-diagnostic tools like the AbC-19 Rapid Test for detecting COVID-19 IgG antibodies and the 2019-nCoV Antigen Test for identifying SARS-CoV-2 antigens. They also offer a range of nucleic acid lateral flow immunoassays, including the PCRD and PCRD FLEX systems, which provide quick readouts following isothermal amplification. The 'Abingdon Simply Test' line further expands their selection of consumer-friendly self-tests. Beyond physical tests, Abingdon Health provides AppDx, an innovative, customizable image-capturing technology that essentially transforms any smartphone into a self-contained lateral flow reader. The company also extends its expertise through a variety of services, including contract manufacturing, bespoke nucleic acid lateral flow test customization, and comprehensive lateral flow development and production. Additionally, they offer strategic consultancy to businesses operating within the healthcare technology sector. Notably, Abingdon Health Plc maintains a significant collaboration and co-marketing agreement with Abcam plc. Founded in 2008, the company's operations are centrally managed from its headquarters in York, United Kingdom.
IPO date
Dec 15, 2020
Employees
74
Domiciled in
GB
Incorporated in
GB

Valuation

No data to show